Use of laquinimod in high doses for the treatment of Multiple sclerosis

摘要

Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome, Methods for treating a Human subject by providing neuroprotection to the Human subject.And Methods for treating a Human Patient affected by multiple sclerosis or presents a clinically isolated syndrome by increasing the time to progression of disease is confirmed, the increased time to Relapse or confirmed the reduction in brain atrophy Human patient,Which comprises administering to the Human Patient or subject orally Daily doses of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof.This also provides an oral pharmaceutical dosage Unit of approximately 1.2 mg laquinimod or a pharmaceutically acceptable Salt thereof and a pharmaceutically acceptable vehicle for use in the treatment of a Human Patient affected by multiple sclerosis or P Introduced a clinically isolated Syndrome,For use in the treatment of a Human subject by providing neuroprotection to the Human subject, or for use in the treatment of a Human Patient affected by multiple sclerosis or presents a clinically isolated Syndrome through the increased time to progression Disease was confirmed,The increased time to Relapse or confirmed the reduction of Brain atrophy in the Human patient.